CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 36 enrolled
Drug / intervention
Lithium +1 moredrug
Likely dose
Lithium 900mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00548964
NCT00548964Phase 1Completed
CompareCT.gov

Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention

James Murrough·interventional·Posted Oct 25, 2007·Updated May 23, 2014

In Brief

A Phase 1 clinical trial evaluating Lithium and Ketamine for Major Depressive Disorder. Completed, enrolled 36 participants across 1 site.

Detailed Summary

As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic (a drug used to produce loss of consciousness before and during surgery). Ketamine is not approved for the treatment of major depressive disorder and is considered experimental in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 25, 2007
Enrollment StartOct 1, 2007
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 18.7 years ago

Interventions

Lithiumdrug

600-900mg of Li carbonate

Ketaminedrug

0.5mg/kg of ketamine